Chromogranin A: Any relevance in neuroendocrine tumors?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 1, 2016, Pages 28-37

  Kidd, Mark ^a   Bodei, Lisa ^b   Modlin, Irvin M ^c  

^a Wren Laboratories   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Chromogranin A; Multianalyte; Multianalyte transcript assay with algorithmic analysis; NETest; Neuroendocrine tumor; Transcript

Indexed keywords

CHROMOGRANIN A; TUMOR MARKER;

ACUTE CORONARY SYNDROME; ATROPHIC GASTRITIS; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; COLORECTAL CANCER; DIAGNOSTIC VALUE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; GIANT CELL ARTERITIS; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LIVER CIRRHOSIS; METASTASIS; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREATITIS; PREDICTIVE VALUE; PROSTATE CANCER; RADIOIMMUNOASSAY; RADIOIMMUNOASSAY KIT; REPRODUCIBILITY; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; THYROID CANCER; BLOOD;

BIOMARKERS, TUMOR; CHROMOGRANIN A; HUMANS; NEUROENDOCRINE TUMORS;

EID: 84952629979     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000215     Document Type: Review

References (61)

1. Feldman SA, Eiden LE. The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 2003; 14:3-23.
2. Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A: biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427-2443.
3. Schimmack S, Svejda B, Lawrence B, et al. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011; 396:273-298.
4. Lee JC, Hook V. Proteolytic fragments of chromogranins A and B represent major soluble components of chromaffin granules, illustrated by two-dimensional proteomics with NH(2)-terminal Edman peptide sequencing and MALDI-TOF MS. Biochemistry 2009; 48:5254-5262.
5. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012; 26:791-802.
6. Lawrence B, Gustafsson BI, Kidd M, et al. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40:111-134.
7. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001; 106:499-509.
8. Chieregatti E, Witkin JW, Baldini G. SNAP-25 and synaptotagmin 1 function in Ca2+-dependent reversible docking of granules to the plasma membrane. Traffic 2002; 3:496-511.
9. Portela-Gomes GM, Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem 2001; 49:483-490.
10. Marotta V, Nuzzo V, Ferrara T, et al. Limitations of chromogranin A in clinical practice. Biomarkers 2012; 17:186-191.
11. Stridsberg M, Oberg K, Li Q, et al. Measurement of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49-59.
12. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337-341.
13. Verderio P, Dittadi R, Marubini E, et al. An Italian program of External Quality Control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clin Chem Lab Med 2007; 45:1244-1250.
14. Gruson D, Lepoutre T, Smits F. Chromogranin-A levels measured with automated immunoassay. Int J Biol Markers 2015; 30:e132-e135.
15. Wolf M, Riedlinger I, Lehmann R, et al. Comparison of the automated KRYPTOR chromogranin A assay with the DAKO ELISA. Clin Lab 2014; 60:2103-2106.
16. Popovici T, Moreira B, Schlageter MH, Bories PN. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A. Clin Biochem 2014; 47 (1-2):87-91.
17. AACC. Chromogranin A [Electronic]. American Association for Clinical Chemistry; 2010. Details regarding chromogranin A as a test. www.jourlib. org/references/11254105 [Accessed 17 November 2015].
18. Woltering EA, Hilton RS, Zolfoghary CM, et al. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 2006; 33:250-254.
19. Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res 1999; 8:113-134.
20. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2:566-580.
21. Oberg K, Modlin I, DeHerder W, et al. Consensus on biomarkers for neuroendocrine tumor Disease. Lancet Oncol 2015; 16:e435-e446.
22. Biomarkers on a roll. Nat Biotechnol 2010; 28:431.
23. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18(suppl 1):S17-S25.
24. Cimitan M, Buonadonna A, Cannizzaro R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003; 14:1135-1141.
25. Jilesen AP, Busch OR, van Gulik TM, et al. Standard pre and postoperative determination of chromogranin a in resectable nonfunctioning pancreatic neuroendocrine tumors-diagnostic accuracy: NF-pNET and low tumor burden. Dig Surg 2014; 31:407-414.
26. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6:820-827.
27. Hijioka M, Ito T, Igarashi H, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci 2014; 105:1464-1471.
28. Qiao XW, Qiu L, Chen YJ, et al. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014; 14:64.
29. Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One 2015; 10:e0124884.
30. Kulke MH. Neuroendocrine tumors: is there a standard treatment? Gastrointest Cancer Res 2008; 2:152-153.
31. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007; 21:433-455.
32. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311-4318.
33. Welin S, Fjallskog ML, Saras J, et al. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006; 84:42-48.
34. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13:327-333.
35. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86:858-865.
36. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 2007; 14:780-785.
37. Sondenaa K, Sen J, Heinle F, et al. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004; 28:890-895.
38. Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology 2014; 100:240-249.
39. Boyar Cetinkaya R, Vatn M, Aabakken L, et al. Survival and prognostic factors in well differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol 2014; 49:734-741.
40. Korse CM, Bonfrer JM, Aaronson NK, et al. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Neuroendocrinology 2009; 89:296-301.
41. Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 2010; 105:2072-2078.
42. Jensen KH, Hilsted L, Jensen C, et al. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol 2013; 48:70-77.
43. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29:934-943.
44. Wu JT, Erickson AJ, Tsao KC, et al. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 2000; 30:175-178.
45. Sciarra A, Monti S, Gentile V, et al. Chromogranin A expression in familial versus sporadic prostate cancer. Urology 2005; 66:1010-1014.
46. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37:955-964.
47. Modlin IM, Kidd M, Bodei L, et al. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol 2015; 110:1223-1232.
48. Karger S, Wiesner T, Kersting A, et al. Increased chromogranin A and carcinoid syndrome-like symptoms in a patient treated with duloxetine. Endocr Pract 2014; 6:1-12.
49. Sherman SK, Maxwell JE, O'Dorisio MS, et al. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014; 21:2971-2980.
50. Pedersen L, Nybo M. Preanalytical factors of importance for measurement of Chromogranin A. Clin Chim Acta 2014; 436:41-44.
51. Syversen U, Halvorsen T, Marvik R, Waldum HL. Neuroendocrine differentiation in colorectal carcinomas. Eur J Gastroenterol Hepatol 1995; 7:667-674.
52. Syversen U, Ramstad H, Gamme K, et al. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004; 39:969-973.
53. Onal IK, Ibis M, Arhan M. Chromogranin A as a marker of disease activity in inflammatory bowel disease. Scand J Gastroenterol 2014; 2:1-2.
54. Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome. Mol Med Rep 2014; 10:2322-2336.
55. El-Salhy M, Gilja OH, Hausken T. Chromogranin A cells in the stomachs of patients with sporadic irritable bowel syndrome. Mol Med Rep 2014; 10:1753-1757.
56. Tota B, Angelone T, Cerra MC. The surging role of Chromogranin A in cardiovascular homeostasis. Front Chem 2014; 2:64.
57. Engels CC, Ruberta F, Kruijf EMd, et al. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat 2013; 142:323-339.
58. Ramachandran R, Bech P, Murphy KG, et al. Comparison of the utility of Cocaine-and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression. J Clin Endocrinol Metab 2015; 100:1520-1528.
59. Modlin IM, Drozdov I, Alaimo D, et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr Relat Cancer 2014; 21:615-628.
60. Modlin IM, Aslanian H, Bodei L, et al. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocr Connect 2014; 3:215-223.
61. Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer 2014; 14:564.